BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19448675)

  • 1. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.
    Wolyniec K; Wotton S; Kilbey A; Jenkins A; Terry A; Peters G; Stocking C; Cameron E; Neil JC
    Oncogene; 2009 Jul; 28(27):2502-12. PubMed ID: 19448675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.
    Anderson G; Mackay N; Gilroy K; Hay J; Borland G; McDonald A; Bell M; Hassanudin SA; Cameron E; Neil JC; Kilbey A
    J Cell Biochem; 2018 Mar; 119(3):2750-2762. PubMed ID: 29052866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
    Shin J; Yang J; Lee JC; Baek KH
    Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.
    Wajapeyee N; Wang SZ; Serra RW; Solomon PD; Nagarajan A; Zhu X; Green MR
    Blood; 2010 Jun; 115(24):5057-60. PubMed ID: 20421454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic ras and p53 cooperate to induce cellular senescence.
    Ferbeyre G; de Stanchina E; Lin AW; Querido E; McCurrach ME; Hannon GJ; Lowe SW
    Mol Cell Biol; 2002 May; 22(10):3497-508. PubMed ID: 11971980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence.
    Sebastian T; Johnson PF
    Cancer Res; 2009 Mar; 69(6):2588-98. PubMed ID: 19276382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of p38δ expression plays an essential role in oncogenic ras-induced senescence.
    Kwong J; Chen M; Lv D; Luo N; Su W; Xiang R; Sun P
    Mol Cell Biol; 2013 Oct; 33(19):3780-94. PubMed ID: 23878395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence.
    Kortum RL; Johnson HJ; Costanzo DL; Volle DJ; Razidlo GL; Fusello AM; Shaw AS; Lewis RE
    Mol Cell Biol; 2006 Mar; 26(6):2202-14. PubMed ID: 16507997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
    Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
    J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.
    Zaidi SK; Dowdy CR; van Wijnen AJ; Lian JB; Raza A; Stein JL; Croce CM; Stein GS
    Cancer Res; 2009 Nov; 69(21):8249-55. PubMed ID: 19826043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts.
    Zhang F; Zakaria SM; Högqvist Tabor V; Singh M; Tronnersjö S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson LG
    Cell Cycle; 2018; 17(24):2697-2715. PubMed ID: 30526305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
    Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
    Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
    Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
    Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replicative senescence of human fibroblasts: the role of Ras-dependent signaling and oxidative stress.
    Hütter E; Unterluggauer H; Uberall F; Schramek H; Jansen-Dürr P
    Exp Gerontol; 2002; 37(10-11):1165-74. PubMed ID: 12470828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts.
    Huot TJ; Rowe J; Harland M; Drayton S; Brookes S; Gooptu C; Purkis P; Fried M; Bataille V; Hara E; Newton-Bishop J; Peters G
    Mol Cell Biol; 2002 Dec; 22(23):8135-43. PubMed ID: 12417717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype.
    Coppé JP; Rodier F; Patil CK; Freund A; Desprez PY; Campisi J
    J Biol Chem; 2011 Oct; 286(42):36396-403. PubMed ID: 21880712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.
    Peeper DS; Shvarts A; Brummelkamp T; Douma S; Koh EY; Daley GQ; Bernards R
    Nat Cell Biol; 2002 Feb; 4(2):148-53. PubMed ID: 11812999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
    Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
    Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.